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Sickle cell disease is one of the most prevalent hemoglobinopathies 
in the world. In Iran, sickle cell disease is more common in southern 
parts of the country such as Khuzestan province. Retinopathy is 
the most representative ocular complication of sickle cell disease. 
Sickle cell retinopathy is characterized by the vaso-occlusion of 
capillary beds and is classified in two types of proliferative and 
non-proliferative according to presence or absence of vascular 
proliferation in fundus. In non-proliferative sickle cell retinopathy, 
the retinal changes do not involve neovascularization as they 
do in proliferative sickle cell retinopathy. The two most severe 
complication of proliferative sickle cell retinopathy are vitreous 
hemorrhage and retinal detachment, which may lead to visual loss. 
Identification and prompt referral of these patients has a critical role 
in prevention of irreversible visual loss. Newer imaging modalities 
such as ultra-wide field fluorescein angiography, spectral domain 
optical coherence tomography and optical coherence tomography 
angiography are now available. These techniques can detect the 
sickle cell retinopathy in its early stages.
In this review, we briefly discuss the manifestations, diagnosis and 
management of sickle cell retinopathy.
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Introduction
Sickle cell disease (SCD) is one of the most 
common hemoglobinopathies in the world 
with millions of people currently affected 
across the globe 1. The prevalence of SCD in 
southern parts of Iran is high, especially in 
Khuzestan province 2. 
Sickle cell anemia (SCA), which is the 
leading group within SCD, results from a 
point mutation (A-T) in the sixth codon of the 
b-globin gene resulting in the  substitution of 
glutamic acid with valine at position 6 of the 
b globin chain forming hemoglobin sickle (Hb 
S) 3,4. The homozygous Hb S genotype (ie, SS) 
represents a severe common form of SCD 5. 
HbS has different properties compared to 
normal hemoglobin. It polymerizes when 
deoxygenated, leading to cellular alterations 
that changes the red cell shape into a rigid and 
sickled form 6. The most important factor in 
the pathophysiology of SCD is vaso-occlusion, 
which leads to ischemia 7. In addition, multiple 
other events including hemolysis associated 
reduction in nitric oxide bioavailability, 
chronic inflammation, oxidative stress, altered 
red cell adhesive properties, activated white 
blood cells and platelets and finally altered 
hemostasis play a critical role in pathogenesis 
of this disease 8. 
Improved survival in SCD has led to higher 
manifestations of morbidities, which are 
becoming more apparent in older patients 9. 
One of the organs affected in SCD are eyes 5,10. 
Both the anterior and posterior segments of the 
eye can be affected, but ocular manifestations 
in the retina are the most important in terms of 
frequency and visual impairment 11. The blood 
flow in terminal retinal arterioles may be 
decreased by the aggregation of rigid sickled 
cells 12. Under these conditions, the available 
Hb is deoxygenated and cannot supply the 
oxygen demand 12.
In this manuscript, sickle cell retinopathy, its 
manifestations, diagnosis and management 
will be discussed.
Ophthalmic Manifestations of SCD
The pathological process of SCD can affect every 
vascular bed in the eye and in its advanced stage 
has the potential to cause visual loss 13. Ocular 
complications of SCD result from occlusion 
of small eye vessels by sickled erythrocytes 
and may involve both anterior and posterior 
segments including orbit, iris, conjunctiva, uvea, 
and especially retina 11, 14. Among possible 
ocular manifestations, the most representative 
is retinopathy, which can lead to blindness if 
left untreated 11. Sickle cell retinopathy (SCR) 
develops in up to 42 % of patients with SCD 
during the second decade of life 11,15. SCR is 
classified in two types: proliferative and non-
proliferative, which is based on the presence 
or absence of vascular proliferations 5.  
Non-proliferative sickle cell retinopathy 
(NPSCR)
NPSCR, is more commonly observed in 
SCA patients with SS genotype 5. In this 
form of retinopathy, the retinal periphery of 
patients shows bilateral changes like salmon 
patch hemorrhages, iridescent spots, black 
sunbursts and angioid streaks 5,11. The findings 
in the central part of retina include foveal 
avascular zone, arteriovenous tortuosity, and 
central retinal artery occlusion (CRAO), as 
well as peripapillary and perimacular arterial 
occlusion 5,11. CRAO, which results in macular 
ischemia, is a rare but potentially devastating 
cause of blindness in patients with SCA with 
an unpredictable course but potential for visual 
recovery 16.
Proliferative sickle cell retinopathy (PSCR) 
PSCR, which is more commonly observed in 
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SCA patients with SC genotype, is caused by 
the high prevalence of abnormal peripheral 
retinal vasculature and causes some degree of 
visual loss in 5-20 % of patients 5. Older age, 
male gender and history of acute pyelonephritis 
are some risk factors for development of PSCR 
among SCA patients 17-20.
Peripheral changes caused by PSCR generally 
include occlusions of the superficial and deep 
capillary plexus, which cause acute paracentral 
middle maculopathy, leading to thinning of 
macular inner retinal layers 5. These peripheral 
retinal vascular occlusions cause tissue 
ischemia and release of angiogenic mediators 
that promote retinal neovascularization 5. 
Then, this neovascularization grows anteriorly 
from the vascularized to avascular retina and 
shapes the hallmark sign in PSCR patients, which 
is called the ”sea fan configuration“ 5. The sea 
fan configuration is a pre-retinal fibrovascular 
membrane involving primarily the retinal 
nerve fiber and ganglion cell layers 5. Sea 
fan structures spontaneously regress in 
20 %-60 % of patients through the development 
of atrophic lesions or auto-infarction, which 
can explain why most patients maintain good 
vision years after a PSCR event 5. 
Staging
Goldberg 21 has classified the SCR into 
five stages based on its severity: Stage I is 
characterized by peripheral arterial occlusion 
due to decreased deformability of erythrocytes, 
stagnant flow, and thrombosis 5. In stage II 
the peripheral arteriovenous anastomoses 
appear to compensate for hypoxia caused 
in the first stage 5. In stage III, pre-retinal 
neovascularization occurs as a result of 
angiogenic factors from the peripheral 
ischemic retina, forming the retinal sea 
fans 5. Stage IV is characterized by vitreous 
hemorrhage, which is the result of bleeding 
from the neovascularization in previous 
stage 22. Finally, stage five is characterized 
by tractional retinal detachment, which might 
lead to visual loss 14.  
Diagnosis
Diagnosis of SCR is based on typical clinical 
examinations in the presence of a history 
of SCD, including measurement of visual 
acuity and intraocular pressure, complete 
dilated fundoscopy, slit-lamp biomicroscopy, 
retinography, fluorescein angiography, spectral 
domain optical coherence tomography and 
optical coherence tomography angiography 
5,14, 20, 22-28.
Treatment
Treatment for SCR remains palliative 5. 
Chemotherapy (hydroxyurea ± anti- vascular 
endothelial growth factor), as well as 
phlebotomy in conjunction with long-term 
blood transfusions to reduce total content of 
HbS in red cells might be helpful in controlling 
the SCR 5. Conventional local therapies for 
SCR include diathermy, cryotherapy and 
argon or xenon photocoagulation, as well 
as surgical treatment, which is indicated for 
complications of proliferative retinopathy, 
such as retinal detachment and vitreous 
hemorrhage 14, 29, 30.
Discussion
Ophthalmic manifestations of SCA including 
retinopathy are increasing with improved survival 
among patients in recent years 13. General 
practitioners, paediatricians, haematologists 
and ophthalmologists should be aware of 
these ophthalmic manifestations to achieve 
on time diagnosis and treatment. It should be 
noted that the best approach for prevention 
of SCR is reducing the prevalence of SCA 
by controlling the spread of the HbS gene 
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pool, which can be achieved by genetic 
counseling before marriage 5. Since SCR 
among SCA patients results from a systemic 
pathological process causing anemia, 
prevention of SCR can be also achieved 
with better treatment of underlying anemia, 
using several approaches such as increase 
in fetal hemoglobin, erythrocyte hydration, 
use of anti-inflammatory drugs, antioxidant 
therapy, antithrombotic drugs, decreasing 
the HbS by transfusion and apheresis, as well 
as hematopoietic stem cell transplantation 
and gene therapy 14. Hematopoietic stem cell 
transplantation has the potential to cure SCD 
and prevent retinopathy, but this treatment 
may cause complications including infertility, 
graft rejection and graft-versus-host disease 
causing a mortality rate of 5-10 % 17. 
Most studies in different populations, confirm 
the importance of periodic eye exams among 
patients with SCA 5. The development of SCR 
is highly unlikely among patients under 10 
years old, thus serial biannual examinations 
has been suggested for patients with SCA 
older than 10 years to detect SCR in its early 
stages and to consider treatment before severe 
complications 18. 
It should be noted that SCR, especially in its 
proliferative form, is more frequent and more 
severe among patients with SC genotype 
than those patients with SS genotype, which 
necessitates special attention to retinal changes 
among these patients 5,14. 
Conclusion
Eye manifestations of SCA including 
retinopathy are increasing with improved 
survival among patients in recent years. 
Considering that sickle cell retinopathy is 
a complication that might cause blindness 
in affected patients, its on time diagnosis 
and treatment should be a goal for both 
hematologists and ophthalmologists caring 
for these patients. Some new diagnostic and 
treatment modalities have been suggested 
for patients with SCR in recent years. Whether 
these advances may lead to improved 
management and treatment outcomes remain 
unanswered. Further studies especially 
randomized clinical trials with sufficient sample 
size are needed to compare the usefulness of 
these new diagnostic and treatment modalities. 
Future advances in treatment of SCA itself 
might lead to reduction of ophthalmologic 
manifestations  of this disease.
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